Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence.

Abstract

Bispecific antibodies are considered attractive bio-therapeutic agents owing to their ability to target two distinct disease mediators. Cross-arm avidity targeting of antigen double-positive cancer cells over single-positive normal tissue is believed to enhance the therapeutic efficacy, restrict major escape mechanisms and increase tumor-targeting selectivity, leading to reduced systemic toxicity and improved therapeutic index. However, the interplay of factors regulating target selectivity is not well understood and often overlooked when developing clinically relevant bispecific therapeutics. We show in vivo that dual targeting alone is not sufficient to endow selective tumor-targeting, and report the pivotal roles played by the affinity of the individual arms, overall avidity and format valence. Specifically, a series of monovalent and bivalent bispecific IgGs composed of the anti-HER2 trastuzumab moiety paired with affinity-modulated VH and VL regions of the anti-EGFR GA201 mAb were tested for selective targeting and eradication of double-positive human NCI-H358 non-small cell lung cancer target tumors over single-positive, non-target NCI-H358-HER2 CRISPR knock out tumors in nude mice bearing dual-flank tumor xenografts. Affinity-reduced monovalent bispecific variants, but not their bivalent bispecific counterparts, mediated a greater degree of tumor targeting selectivity, while the overall efficacy against the targeted tumor was not substantially affected.

• Authors: Yariv Mazor, Kris F Sachsenmeier, Chunning Yang, Anna Hansen, Jessica Filderman, Kathy Mulgrew, Herren Wu, William F Dall'Acqua
• Journal: Scientific reports (Sci Rep) Vol. 7 Pg. 40098 (01 09 2017) ISSN: 2045-2322 [Electronic] England
• PMID: 28067257 (Publication Type: Journal Article)

Chemical References

• Antibodies, Bispecific
• EGFR protein, human
• ERBB2 protein, human
• ErbB Receptors
• Receptor, ErbB-2
• Trastuzumab

Topics

• Animals
• Antibodies, Bispecific (administration & dosage, immunology)
• Antibody Affinity
• Antibody Specificity
• Carcinoma, Non-Small-Cell Lung (drug therapy, immunology)
• Cell Line, Tumor
• ErbB Receptors (immunology)
• Humans
• Mice, Nude
• Receptor, ErbB-2 (immunology)
• Trastuzumab (administration & dosage, immunology)
• Xenograft Model Antitumor Assays